BioMarin plots comeback year, with plans to turn around profits and head back to the FDA with rejected gene therapy

Nicole DeFeudis

Editor

Could this be a comeback year for BioMarin? CEO Jean-Jacques Bienaimé certainly hopes so, as he plans to finally turn the corner on profitability and send the company’s hemophilia gene therapy back to the FDA.

But there are still a few things analysts want to know. Like, what’s going on with the clinical hold on its phenylketonuria gene therapy? And when will the company seek full approval for Voxzogo, its costly achondroplasia drug that got the FDA’s accelerated approval treatment late last year?

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

BioMarin plots comeback year, with plans to turn around profits and head back to the FDA with rejected gene therapy

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

FDA is ready to eliminate the interchangeability designation for biosimilars

Cash, chips and talent: Inside Nvidia's plan to dominate biotech's AI revolution

Regeneron enters venture investing with $500M, poaches senior partner from ARCH

Federal judge grants pause to Pfizer, BioNTech in Covid-19 patent lawsuit trial brought by Moderna

ADC dealmaking is red hot. Is it sustainable?

New FDA trial innovation center launches with demonstration to increase industry interactions

Bio­Marin plots come­back year, with plans to turn around prof­its and head back to the FDA with re­ject­ed gene ther­a­py

Editor

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

BioMarin plots comeback year, with plans to turn around profits and head back to the FDA with rejected gene therapy